Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

New industry rules require visual size checks or GP medical records for online fat jab purchases. The updated guidelines ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...